Ionis Pharmaceuticals

Phase 3 AI-extracted

eplontersen

ATTR-CM

Resolved

7days ago

Phase 3 readout · ~ Jun 30, 2026 estimated

What's at stake Phase 3 trial results for eplontersen in ATTR-CM are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 12h ago

“Results from Phase 3 CARDIO-TTRansform study of eplontersen, Ionis’ co-commercialized investigational medicine with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) o Results expected in H2 2026”

Add to calendar Post on X Reddit

Provenance